Bristol-Myers Squibb Holdings Limited

Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH , UK
Telephone: +44 (0)1895 52 3000
Fax: +44 (0)1895 52 3010
Medical Information Direct Line: +1 800 749 749
Medical Information e-mail: medical.information@bms.com
Medical Information Fax: +44 (0)1895 523 677

Summary of Product Characteristics last updated on the eMC: 23/01/2012
SPC Vepesid Soft Capsules 50 mg and 100 mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/01/2012 and displayed until Current
Reasons for adding or updating:
  • Addition of Legal Category
Date of revision of text on the SPC:   13-Mar-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Legal Catagory:

POM added
Updated on 01/08/2008 and displayed until 23/01/2012
Reasons for adding or updating:
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   13-Mar-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

None provided
Updated on 14/05/2008 and displayed until 01/08/2008
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   13-Mar-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 1: Product name to include 'soft'

Section 2: Quantitative information about the excipient 'parahydroxybenzoate'
Updated on 08/08/2005 and displayed until 14/05/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 29/04/2005 and displayed until 08/08/2005
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 9 - Date of Renewal of Authorisation
  • Change to section 10 (date of (partial) revision of the text
Updated on 22/08/2001 and displayed until 29/04/2005
Reasons for adding or updating:
  • Transferred from eMC version 1
  • Addition of joint SPC covering all presentations

Active Ingredients/Generics

 
   etoposide